Latimer N - Search Results

1

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.

Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Ouwens MJNM, et al. Among authors: latimer n. Pharmacoeconomics. 2019 Sep;37(9):1129-1138. doi: 10.1007/s40273-019-00806-4. Pharmacoeconomics. 2019. PMID: 31102143 Free PMC article.

2

Adjusting overall survival for treatment switches: commonly used methods and practical application.

Watkins C, Huang X, Latimer N, Tang Y, Wright EJ. Watkins C, et al. Among authors: latimer n. Pharm Stat. 2013 Nov-Dec;12(6):348-57. doi: 10.1002/pst.1602. Epub 2013 Oct 18. Pharm Stat. 2013. PMID: 24136868

3

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC, Luqmani R. Latimer NR, et al. Pharmacoeconomics. 2014 Dec;32(12):1171-83. doi: 10.1007/s40273-014-0189-z. Pharmacoeconomics. 2014. PMID: 25059204 Free PMC article.

4

Treatment switching in oncology trials and the acceptability of adjustment methods.

Latimer NR. Latimer NR. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):561-4. doi: 10.1586/14737167.2015.1037835. Epub 2015 Apr 20. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25893990

5

A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis.

Ren S, Minton J, Whyte S, Latimer NR, Stevenson M. Ren S, et al. Pharmacoeconomics. 2018 Mar;36(3):341-347. doi: 10.1007/s40273-017-0584-3. Pharmacoeconomics. 2018. PMID: 29081060 Free PMC article.

6

Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.

Bullement A, Latimer NR, Bell Gorrod H. Bullement A, et al. Value Health. 2019 Mar;22(3):276-283. doi: 10.1016/j.jval.2018.10.007. Epub 2018 Dec 13. Value Health. 2019. PMID: 30832965 Free article.

7

Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?

Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Woods BS, et al. Among authors: latimer n. Value Health. 2020 Dec;23(12):1613-1621. doi: 10.1016/j.jval.2020.08.2094. Epub 2020 Oct 17. Value Health. 2020. PMID: 33248517 Free article.

8

Not cost-effective at zero price: valuing and paying for combination therapies in cancer.

Latimer NR, Towse A, Henshall C. Latimer NR, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):331-333. doi: 10.1080/14737167.2021.1879644. Epub 2021 Feb 9. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33472440 Free article. No abstract available.

9

Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.

Tai TA, Latimer NR, Benedict Á, Kiss Z, Nikolaou A. Tai TA, et al. Value Health. 2021 Apr;24(4):505-512. doi: 10.1016/j.jval.2020.10.016. Epub 2020 Dec 8. Value Health. 2021. PMID: 33840428 Free article.

10

Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals.

Srivastava T, Latimer NR, Tappenden P. Srivastava T, et al. Pharmacoeconomics. 2021 Aug;39(8):869-878. doi: 10.1007/s40273-021-01034-5. Epub 2021 May 19. Pharmacoeconomics. 2021. PMID: 34008137 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters